You are hereFebruary 16, 2021
Neurotrophin‐3 Protects Cardiovascular Progenitor Cells from I/R-Injury
While implantation of human embryonic stem cell‐derived cardiovascular progenitor cells (hCVPCs) can promote the recovery of infarcted hearts via paracrine action, the contribution of secreted factors remains identified. Now, a new STEM CELLS Translational Medicine study from the lab of Huang‐Tian Yang (Chinese Academy of Science, Shanghai, China) has revealed neurotrophin (NT)‐3 secretion by hCVPCs and enhanced secretion during mouse myocardial ischemia/reperfusion (I/R) injury. Injection of NT‐3 mimics the beneficial effect of hCVPCs in I/R hearts via suppressing cardiomyocyte apoptosis through modulation of the ERK‐Bim signaling pathway and promoting angiogenesis. Overall, Bi et al. reveal a new function of NT‐3 in hCVPCs and I/R hearts and indicate a potential therapeutic role for cell products in the treatment of ischemic heart disease.